Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could antibiotics tame sarcoidosis? new study investigates

NCT ID NCT05291468

Disease control Sponsor: St. Antonius Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a combination of two antibiotics (azithromycin and doxycycline) can reduce bacteria linked to sarcoidosis and lower inflammation. About 40 adults with biopsy-confirmed sarcoidosis and active inflammation on a PET scan will receive the antibiotics or a placebo. The goal is to see if targeting the bacteria improves disease activity and quality of life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2023

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Biopsy proven sarcoidosis. * No treatment indication for the sarcoidosis * Inflammatory activity according to FDG-PET scan at baseline * SUVmax above 3 in the lung and/or above 5 in mediastinum/hili Exclusion Criteria: * Increased duration of QT interval (\>440ms for men and \>450ms for women) on ECG * Hearing deficits, as this is a possible side effect of azithromycin * Being pregnant or breastfeeding at time of inclusion

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Sarcoidosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pulmonary sarcoidosis sarcoidosis skin sarcoidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Sarcoidosis skin Sarcoidosis, pulmonary

Contacts and locations

Locations

  • St. Antonius Hospital

    Nieuwegein, Utrecht, 3435 CM, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.